HealthRX.com · Printable medication review sheet
After pancreatitis on Mounjaro: choosing the next medicine
Bring this to the follow-up visit after a pancreatitis episode. It records what happened and what caused it, lists the risk factors to review, and gives a table for comparing replacement options for blood sugar, weight or both, with the trial figures this page relies on.
The episode
Date the pain started
Last Mounjaro dose (mg) and date
Lipase result and date
Imaging done and what it showed
Cause the team identifiedgallstones, alcohol, high triglycerides, another medicine, none found
Hospital stay, if any
Risk factors to go through with the doctor
- Gallstones or other gallbladder disease
- Alcohol use
- High triglycerides
- Another medicine linked to pancreatitis, such as valproic acid or azathioprine
- A pancreatitis episode before Mounjaro
- No cause found yet
Options to compare
Fill in what your prescriber tells you about each option you discuss.
| Medicine or class | Helps glucose, weight or both | How it is taken | Works through incretins? | Trade-offs I was told about | Covered by my plan? |
|---|---|---|---|---|---|
| SGLT2 inhibitor | |||||
| Metformin | |||||
| Pioglitazone | |||||
| Basal insulin | |||||
| DPP-4 inhibitor | Yes | ||||
| Phentermine/topiramate or naltrexone/bupropion | |||||
From the label and the trials on this page
- The Mounjaro label: if pancreatitis is suspected, stop Mounjaro and start appropriate care.[1]
- The label's pancreatitis warning covers GLP-1 receptor agonists as well as Mounjaro.[1]
- Adjudicated acute pancreatitis in Mounjaro's clinical studies: 13 patients (0.23 per 100 years of exposure) against 3 on comparators (0.11).[1]
- TECOS (sitagliptin, an incretin-based tablet): no significant difference from placebo in acute pancreatitis.[2]
- EQUIP: phentermine/topiramate 15/92 mg, 10.9% weight loss at 56 weeks against 1.6% on placebo.[3]
- COR-I: naltrexone/bupropion 32 mg, 6.1% weight loss against 1.3% on placebo; nausea in 29.8% against 5.3%.[4]
Questions for the follow-up visit
- Was a cause other than Mounjaro found, and does that change which medicines are safe for me?
- Should I avoid every incretin-based medicine, including DPP-4 inhibitors?
- Is my main goal now blood sugar, weight, or both, and which option fits that?
- When should my lipase, triglycerides or imaging be checked again?
- What should I expect my HbA1c and weight to do in the months after stopping?
Sources for the facts on this sheet
- Eli Lilly and Company, via DailyMed. Mounjaro (tirzepatide) injection, for subcutaneous use: prescribing information and Medication Guide. Effective 2026-08-27. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015. PMID 26052984. https://pubmed.ncbi.nlm.nih.gov/26052984/
- Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012. PMID 22051941. https://pubmed.ncbi.nlm.nih.gov/22051941/
- Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010. PMID 20673995. https://pubmed.ncbi.nlm.nih.gov/20673995/
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.